Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Public Health and Preventive Medicine
  4. Vol 3, Issue 6, 2023

The relationship between gene mutations and age and gender in patients with first-onset acute myeloid leukemia

Download as PDF

DOI: 10.23977/phpm.2023.030609 | Downloads: 6 | Views: 235

Author(s)

Yuting Chen 1, Xiaohua Luo 1

Affiliation(s)

1 Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China

Corresponding Author

Xiaohua Luo

ABSTRACT

AML is a malignant clonal disease whose incidence is proportional to age, with men more likely than women to develop the disease.  With the advancement of next-generation sequencing technology, people have become increasingly aware that the clonal evolution of leukemia is a complex, staged, multi-gene mutation process.  In the AML diagnosis and treatment guidelines in recent years, gene mutations such as NPM1, FLT3-ITD and C-Kit have been used to assess the prognostic risk of AML.  This article will review the previous literature and conduct a summary analysis of the age and gender differences in several common gene mutations in patients with first-episode AML, in order to help unearth the pathogenesis of AML, clinical treatment and prognosis judgment.

KEYWORDS

Acute myeloid leukemia, genetic mutations, age and gender differences

CITE THIS PAPER

Yuting Chen, Xiaohua Luo, The relationship between gene mutations and age and gender in patients with first-onset acute myeloid leukemia. MEDS Public Health and Preventive Medicine (2023) Vol. 3: 60-64. DOI: http://dx.doi.org/10.23977/phpm.2023.030609.

REFERENCES

[1] AUNG M M K, MILLS M L, BITTENCOURT-SILVESTRE J, et al. Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia  [J]. Mol Oncol, 2021, 15(9): 2253-2272.
[2] SHIBA N, YOSHIDA K, SHIRAISHI Y, et al. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia [J]. Br J Haematol, 2016, 175(3): 476-489.
[3] LAING A A, HARRISON C J, GIBSON B E S, et al. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia [J]. Exp Hematol, 2017, 54: 40-50.
[4] JAISWAL   S,   FONTANILLAS   P,   FLANNICK   J,   et   al.   Age-related   clonal hematopoiesis associated with adverse outcomes [J]. N Engl J Med, 2014, 371(26):2488-2498.
[5] BOLOURI H, FARRAR J E, TRICHE T, JR., et al. The molecular landscape of pediatric acute  myeloid  leukemia  reveals  recurrent  structural  alterations  and age-specific mutational interactions [J]. Nat Med, 2018, 24(1): 103- 112.
[6] FARRAR J E, SCHUBACK H L, RIES R E, et al. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse [J]. Cancer Res, 2016, 76(8): 2197-2205.
[7] TYNER J W, TOGNON C E, BOTTOMLY D, et al. Functional genomic landscape of acute myeloid leukaemia [J]. Nature, 2018, 562(7728): 526-531.
[8] PAPAEMMANUIL   E,    GERSTUNG   M,   BULLINGER    L,    et   al.    Genomic Classification and Prognosis in Acute Myeloid Leukemia [J]. N Engl J Med, 2016, 374(23): 2209-2221.
[9] CREANEY J, DICK I M, ROBINSON B W. Discovery  of new biomarkers for malignant mesothelioma [J]. Curr Pulmonol Rep, 2015, 4( 1): 15-21.
[10] TARLOCK K, HANSEN M E, HYLKEMA T, et al. Discovery  and FunctionalValidation  of Novel  Pediatric  Specific  FLT3  Activating  Mutations  in  Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative [J]. Blood, 2015, 126(23): 87-.
[11] JULIUSSON G, JÄDERSTEN M, DENEBERG S, et al. The prognostic impact of FLT3-ITD   and   NPM1   mutation in adult AML is age-dependent   in   the population-based setting [J]. Blood Adv, 2020, 4(6): 1094- 1101.
[12] METZELER K H, HEROLD T, ROTHENBERG-THURLEY M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia [J]. Blood, 2016, 128(5): 686-698.
[13] LOGHAVI S, ZUO  Z,  RAVANDI  F,  et  al.  Clinical  features  of de  novo  acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations [J]. J Hematol Oncol, 2014, 7: 74.
[14] Xiang Guoqiang, Zeng Yun. Progress in gene mutation studies in acute myeloid leukemia [J]. Journal of Clinical Hematology, 2013, 26 (11): 808-812.
[15] HOLLINK I H, FENG Q, DANEN-VAN OORSCHOT AA, et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model [J]. Leukemia, 2012, 26(2): 371-374.
[16] LI Y, ZHANG D  F, ZHANG  S  W,  et  al.  Screening  for  mutation  R882  in  the DNMT3A gene in Chinese patients with hematological disease [J]. Int J Hematol, 2012, 96(2): 229-233.
[17] ENGEN  C,  GROB  T,  et  al.  Sex  disparity  in  acute  myeloid leukaemia  with  FLT3  internal  tandem  duplication  mutations:  implications  for prognosis [J]. Mol Oncol, 2021, 15(9): 2285-2299.
[18] THIEDE C, KOCH S, CREUTZIG E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) [J]. Blood, 2006, 107( 10): 4011-4020.
[19] CHOU W C, TANG J L, LIN L I, et al. Nucleophosmin mutations in de novo acutemyeloid leukemia: the age-dependent incidences and the stability during disease evolution [J]. Cancer Res, 2006, 66(6): 3310-3316.
[20] CAZZANIGA G, DELL'ORO M G, MECUCCI C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype [J]. Blood, 2005, 106(4): 1419-1422.
[21] BROWN P, MCINTYRE E, RAU R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML [J]. Blood, 2007, 110(3): 979-785.
[22] POLLARD J A, ALONZO T A, GERBING R B, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML [J]. Blood, 2010, 115(12): 2372-2379.
[23] QIN Y Z, ZHU H H, JIANG Q, et al. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study  from  a  single  Chinese  center   [J].  Leuk  Res,  2014,  38( 12):1435-1440.
[24] Aravind L, Iyer LM. The HARE-HTH and associated domains: Novel modules in the coordination of epigenetic DNA and protein modifications[J]. Cell Cycle. 2012;11(1):119–131. 
[25] Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW, Müller J. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB[J]. Nature. 2010; 465: 243–247.
[26] Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases [J]. J Hematol Oncol. 2012; 5:12. 
[27] METZELER K H, HEROLD T, ROTHENBERG-THURLEY M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia [J]. Blood, 2016, 128(5): 686-698.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 1824
Visits: 85489

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.